as 12-20-2024 4:00pm EST
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | N/A |
Market Cap: | 2.1B | IPO Year: | 2022 |
Target Price: | $89.00 | AVG Volume (30 days): | 62.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.11 | EPS Growth: | N/A |
52 Week Low/High: | $31.01 - $86.53 | Next Earning Date: | 11-12-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BLTE Breaking Stock News: Dive into BLTE Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
MT Newswires
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "BLTE Belite Bio Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.